---
document_datetime: 2025-12-29 14:36:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sibnayal.html
document_name: sibnayal.html
version: success
processing_time: 0.0954687
conversion_datetime: 2025-12-30 13:02:16.366198
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sibnayal

[RSS](/en/individual-human-medicine.xml/67408)

##### Authorised

This medicine is authorised for use in the European Union

potassium citrate / potassium hydrogen carbonate Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sibnayal](#news-on)
- [More information on Sibnayal](#more-information-on-sibnayal-921)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sibnayal is a medicine used to treat patients from the age of one year with distal renal tubular acidosis (dRTA), a disease in which the kidneys do not remove acid through the urine well enough. This results in a build-up of acid in the blood, which leads to a range of symptoms including hearing and growth problems, vomiting, kidney stones and lack of alertness. The disease also causes levels of potassium in the blood to fall, which can lead to muscle weakness and paralysis.

Sibnayal contains the active substances potassium citrate and potassium hydrogen carbonate.

Expand section

Collapse section

## How is Sibnayal used?

Sibnayal is available as prolonged-release granules to be taken by mouth, and can only be obtained with a prescription. Prolonged release means that the active substance in Sibnayal is released slowly into the body over a few hours after being taken. The starting dose depends on the age and body weight of the patient, and is gradually increased to obtain the optimal dose that provides adequate control of acid and potassium levels in the blood. Sibnayal is taken twice daily, typically twelve hours apart.

For more information about using Sibnayal, see the package leaflet or contact your doctor or pharmacist.

## How does Sibnayal work?

Sibnayal contains a combination of two salts, potassium citrate and potassium hydrogen carbonate. Because the combination is alkaline and contains potassium, it neutralises excess acid in the blood and restores levels of potassium, thus relieving the symptoms of the disease.

## What benefits of Sibnayal have been shown in studies?

One study in 37 patients with dRTA showed that Sibnayal was effective at reducing the level of acid and normalising the level of potassium in the blood.

Patients were first treated with their usual medicines for neutralising excess acid for 5 days, then switched to Sibnayal. The optimal dose of Sibnayal was reached gradually over 30 days, after which patients were given this dose for at least 5 days.

The large majority (90%) of patients had a reduction in blood acid levels during treatment with Sibnayal, and this effect was generally maintained during 24 months of treatment. In addition, blood potassium levels returned to normal in 83% of patients. The corresponding figures during treatment with other medicines were 45% and 82%, respectively.

## What are the risks associated with Sibnayal?

The most common side effects with Sibnayal (which may affect more than 1 in 10 people) is abdominal (belly) pain. Nausea (feeling sick) at start of treatment, stomach pain and gut pain may affect up to 1 in 10 people. For the full list of side effects of Sibnayal, see the package leaflet.

Sibnayal must not be used in patients with moderately or severely impaired kidney function and in patients with hyperkalaemia (high blood potassium levels). For the full list of restrictions, see the package leaflet.

## Why is Sibnayal authorised in the EU?

Sibnayal was shown to be effective at reducing the level of acid and normalising the level of potassium in dRTA patients' blood. The safety of Sibnayal was considered acceptable, and its side effects manageable and in line with other treatments for this disease. The European Medicines Agency therefore decided that Sibnayal's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Sibnayal?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sibnayal have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sibnayal are continuously monitored. Side effects reported with Sibnayal are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sibnayal

Sibnayal received a marketing authorisation valid throughout the EU on 30 April 2021.

Sibnayal : EPAR - Medicine overview

English (EN) (120.89 KB - PDF)

**First published:** 03/05/2021

[View](/en/documents/overview/sibnayal-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-284)

български (BG) (165.51 KB - PDF)

**First published:**

03/05/2021

[View](/bg/documents/overview/sibnayal-epar-medicine-overview_bg.pdf)

español (ES) (127.55 KB - PDF)

**First published:**

03/05/2021

[View](/es/documents/overview/sibnayal-epar-medicine-overview_es.pdf)

čeština (CS) (162.83 KB - PDF)

**First published:**

03/05/2021

[View](/cs/documents/overview/sibnayal-epar-medicine-overview_cs.pdf)

dansk (DA) (136.92 KB - PDF)

**First published:**

03/05/2021

[View](/da/documents/overview/sibnayal-epar-medicine-overview_da.pdf)

Deutsch (DE) (141.49 KB - PDF)

**First published:**

03/05/2021

[View](/de/documents/overview/sibnayal-epar-medicine-overview_de.pdf)

eesti keel (ET) (125.66 KB - PDF)

**First published:**

03/05/2021

[View](/et/documents/overview/sibnayal-epar-medicine-overview_et.pdf)

ελληνικά (EL) (159.95 KB - PDF)

**First published:**

03/05/2021

[View](/el/documents/overview/sibnayal-epar-medicine-overview_el.pdf)

français (FR) (140.68 KB - PDF)

**First published:**

03/05/2021

[View](/fr/documents/overview/sibnayal-epar-medicine-overview_fr.pdf)

hrvatski (HR) (162.06 KB - PDF)

**First published:**

03/05/2021

[View](/hr/documents/overview/sibnayal-epar-medicine-overview_hr.pdf)

italiano (IT) (137.02 KB - PDF)

**First published:**

03/05/2021

[View](/it/documents/overview/sibnayal-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (168.03 KB - PDF)

**First published:**

03/05/2021

[View](/lv/documents/overview/sibnayal-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (160.33 KB - PDF)

**First published:**

03/05/2021

[View](/lt/documents/overview/sibnayal-epar-medicine-overview_lt.pdf)

magyar (HU) (157.64 KB - PDF)

**First published:**

03/05/2021

[View](/hu/documents/overview/sibnayal-epar-medicine-overview_hu.pdf)

Malti (MT) (170.91 KB - PDF)

**First published:**

03/05/2021

[View](/mt/documents/overview/sibnayal-epar-medicine-overview_mt.pdf)

Nederlands (NL) (137.91 KB - PDF)

**First published:**

03/05/2021

[View](/nl/documents/overview/sibnayal-epar-medicine-overview_nl.pdf)

polski (PL) (161.84 KB - PDF)

**First published:**

03/05/2021

[View](/pl/documents/overview/sibnayal-epar-medicine-overview_pl.pdf)

português (PT) (139.01 KB - PDF)

**First published:**

03/05/2021

[View](/pt/documents/overview/sibnayal-epar-medicine-overview_pt.pdf)

română (RO) (160.81 KB - PDF)

**First published:**

03/05/2021

[View](/ro/documents/overview/sibnayal-epar-medicine-overview_ro.pdf)

slovenčina (SK) (160.92 KB - PDF)

**First published:**

03/05/2021

[View](/sk/documents/overview/sibnayal-epar-medicine-overview_sk.pdf)

slovenščina (SL) (158.6 KB - PDF)

**First published:**

03/05/2021

[View](/sl/documents/overview/sibnayal-epar-medicine-overview_sl.pdf)

Suomi (FI) (135.97 KB - PDF)

**First published:**

03/05/2021

[View](/fi/documents/overview/sibnayal-epar-medicine-overview_fi.pdf)

svenska (SV) (136.5 KB - PDF)

**First published:**

03/05/2021

[View](/sv/documents/overview/sibnayal-epar-medicine-overview_sv.pdf)

Sibnayal : EPAR - Risk-management-plan summary

English (EN) (93.77 KB - PDF)

**First published:** 03/05/2021

[View](/en/documents/rmp-summary/sibnayal-epar-risk-management-plan-summary_en.pdf)

## Product information

Sibnayal : EPAR - Product information

English (EN) (534.47 KB - PDF)

**First published:** 03/05/2021

**Last updated:** 16/05/2025

[View](/en/documents/product-information/sibnayal-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-325)

български (BG) (604.84 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/bg/documents/product-information/sibnayal-epar-product-information_bg.pdf)

español (ES) (549.24 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/es/documents/product-information/sibnayal-epar-product-information_es.pdf)

čeština (CS) (560.74 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/cs/documents/product-information/sibnayal-epar-product-information_cs.pdf)

dansk (DA) (527.47 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/da/documents/product-information/sibnayal-epar-product-information_da.pdf)

Deutsch (DE) (546.51 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/de/documents/product-information/sibnayal-epar-product-information_de.pdf)

eesti keel (ET) (527.24 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/et/documents/product-information/sibnayal-epar-product-information_et.pdf)

ελληνικά (EL) (618.4 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/el/documents/product-information/sibnayal-epar-product-information_el.pdf)

français (FR) (558.39 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/fr/documents/product-information/sibnayal-epar-product-information_fr.pdf)

hrvatski (HR) (590.35 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/hr/documents/product-information/sibnayal-epar-product-information_hr.pdf)

íslenska (IS) (545.84 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/is/documents/product-information/sibnayal-epar-product-information_is.pdf)

italiano (IT) (562.55 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/it/documents/product-information/sibnayal-epar-product-information_it.pdf)

latviešu valoda (LV) (621.16 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/lv/documents/product-information/sibnayal-epar-product-information_lv.pdf)

lietuvių kalba (LT) (577.48 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/lt/documents/product-information/sibnayal-epar-product-information_lt.pdf)

magyar (HU) (606.96 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/hu/documents/product-information/sibnayal-epar-product-information_hu.pdf)

Malti (MT) (630.44 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/mt/documents/product-information/sibnayal-epar-product-information_mt.pdf)

Nederlands (NL) (547.38 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/nl/documents/product-information/sibnayal-epar-product-information_nl.pdf)

norsk (NO) (542.9 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/no/documents/product-information/sibnayal-epar-product-information_no.pdf)

polski (PL) (617.45 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/pl/documents/product-information/sibnayal-epar-product-information_pl.pdf)

português (PT) (549.38 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/pt/documents/product-information/sibnayal-epar-product-information_pt.pdf)

română (RO) (579.72 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/ro/documents/product-information/sibnayal-epar-product-information_ro.pdf)

slovenčina (SK) (604.13 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/sk/documents/product-information/sibnayal-epar-product-information_sk.pdf)

slovenščina (SL) (562.19 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/sl/documents/product-information/sibnayal-epar-product-information_sl.pdf)

Suomi (FI) (530.38 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/fi/documents/product-information/sibnayal-epar-product-information_fi.pdf)

svenska (SV) (527.69 KB - PDF)

**First published:**

03/05/2021

**Last updated:**

16/05/2025

[View](/sv/documents/product-information/sibnayal-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000267097 16/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sibnayal : EPAR - All authorised presentations

English (EN) (66.43 KB - PDF)

**First published:** 03/05/2021

[View](/en/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-496)

български (BG) (79.74 KB - PDF)

**First published:**

03/05/2021

[View](/bg/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_bg.pdf)

español (ES) (67.61 KB - PDF)

**First published:**

03/05/2021

[View](/es/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_es.pdf)

čeština (CS) (81.09 KB - PDF)

**First published:**

03/05/2021

[View](/cs/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (66.58 KB - PDF)

**First published:**

03/05/2021

[View](/da/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (65.73 KB - PDF)

**First published:**

03/05/2021

[View](/de/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (70.7 KB - PDF)

**First published:**

03/05/2021

[View](/et/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (84.48 KB - PDF)

**First published:**

03/05/2021

[View](/el/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_el.pdf)

français (FR) (66.52 KB - PDF)

**First published:**

03/05/2021

[View](/fr/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (89.18 KB - PDF)

**First published:**

03/05/2021

[View](/hr/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (48.18 KB - PDF)

**First published:**

03/05/2021

[View](/is/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_is.pdf)

italiano (IT) (67.02 KB - PDF)

**First published:**

03/05/2021

[View](/it/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (86.54 KB - PDF)

**First published:**

03/05/2021

[View](/lv/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (89.36 KB - PDF)

**First published:**

03/05/2021

[View](/lt/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (84.93 KB - PDF)

**First published:**

03/05/2021

[View](/hu/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (89.68 KB - PDF)

**First published:**

03/05/2021

[View](/mt/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (66.4 KB - PDF)

**First published:**

03/05/2021

[View](/nl/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (52.63 KB - PDF)

**First published:**

03/05/2021

[View](/no/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_no.pdf)

polski (PL) (88.04 KB - PDF)

**First published:**

03/05/2021

[View](/pl/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_pl.pdf)

português (PT) (68.98 KB - PDF)

**First published:**

03/05/2021

[View](/pt/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_pt.pdf)

română (RO) (81.96 KB - PDF)

**First published:**

03/05/2021

[View](/ro/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (91.88 KB - PDF)

**First published:**

03/05/2021

[View](/sk/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (89.01 KB - PDF)

**First published:**

03/05/2021

[View](/sl/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (64.32 KB - PDF)

**First published:**

03/05/2021

[View](/fi/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (66.06 KB - PDF)

**First published:**

03/05/2021

[View](/sv/documents/all-authorised-presentations/sibnayal-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sibnayal Active substance

- potassium citrate monohydrated
- potassium hydrogen carbonate

International non-proprietary name (INN) or common name

- potassium citrate
- potassium hydrogen carbonate

Therapeutic area (MeSH) Acidosis, Renal Tubular Anatomical therapeutic chemical (ATC) code A12BA30

### Pharmacotherapeutic group

Mineral supplements

### Therapeutic indication

Sibnayal is indicated for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older.

## Authorisation details

EMA product number EMEA/H/C/005407 Marketing authorisation holder

Advicenne S.A.

262 rue du Faubourg Saint Honoré

Opinion adopted 10/12/2020 Marketing authorisation issued 30/04/2021 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sibnayal : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (123.77 KB - PDF)

**First published:** 16/05/2025

[View](/en/documents/procedural-steps-after/sibnayal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sibnayal : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (175.79 KB - PDF)

**First published:** 26/04/2022

**Last updated:** 16/05/2025

[View](/en/documents/procedural-steps-after/sibnayal-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Sibnayal : Orphan designation withdrawal assessment report (initial authorisation)

Adopted

Reference Number: EMA/OD/0000032257

English (EN) (324.5 KB - PDF)

**First published:** 03/05/2021

[View](/en/documents/orphan-maintenance-report/sibnayal-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Sibnayal : EPAR - Public assessment report

Adopted

Reference Number: EMA/1419/2021

English (EN) (2.98 MB - PDF)

**First published:** 03/05/2021

[View](/en/documents/assessment-report/sibnayal-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sibnayal

Adopted

Reference Number: EMA/CHMP/650319/2020

English (EN) (132.31 KB - PDF)

**First published:** 11/12/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sibnayal_en.pdf)

#### News on Sibnayal

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020) 11/12/2020

#### More information on Sibnayal

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](https://www.ema.europa.eu/node/32557) on 20 June 2017. The product was withdrawn from the Union Register of orphan medicinal products by the European Commission in March 2021 upon request of the marketing authorisation holder at the time of the granting of a marketing authorisation.

**This page was last updated on** 16/05/2025

## Share this page

[Back to top](#main-content)